Sharekhan has given Buy recommendation for Gland Pharma with a target price of Rs. 3040 in its research report issued on Feb 26, 2021

Sharekhan’s research report on Gland Pharma

Gland is an established player in Injectables space and is well-placed to harness the growth opportunities in this space. It has a strong compliance record with nil observations from the USFDA across all its plants. Gland has a unique B2B business model, which enables it grow its market share while maintaining cost leadership. Strong domain expertise, robust growth prospects, sturdy & consistent earnings track record, and healthy return ratios make Gland an ideal long-term investment pick.

Outlook

We Initiate coverage on Gland Pharma Limited (Gland) with a Buy recommendation and a price target of Rs. 3,040.

Leave a Reply

Your email address will not be published. Required fields are marked *